undamentalytics Newsletter
Sign in

Cormedix Inc. income statement

In fiscal 2025, Cormedix Inc. reported revenue of $312m, up 617.0% on the year before, operating income of $150m (a 48.2% margin) and net income of $163m, or $2.04 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222024Dec 20242025Dec 2025LTMJun 2026
Revenue0000000000043312462
Cost of revenue0−0−0−00000000322—
Gross profit0−0−0−0−000−000040276383
Research and development11161624191113131141928
Selling, general and administrative——————810141620———
Selling and marketing———————————293852
General and administrative2371099—————306886
Operating income−3−5−9−17−25−33−27−21−27−29−31−22150217
Interest expense0100000100003—
Net interest income———————————1——
Income before tax−3−9−20−18−25−33−27−21−27−29−30−19150203
Income tax00—————−5−5−1−1−1−1316
Net income−3−9−20−18−25−33−27−16−22−28−30−18163187
Diluted EPS−$0.90−$2.07−$2.88−$1.74−$1.95−$1.80−$1.51−$1.80−$0.77−$0.75−$0.74−$0.30$2.04—
Diluted shares (average)4m5m7m10m13m18m18m24m29m38m40m59m80m—
EBITDA−3−5−9−17−25−33−27−21−27−29−31−22151238

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ARQT vs CRMDCRMD vs KRYSARDX vs CRMD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cormedix Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cormedix Inc.